Mendus
- Biotech or pharma, therapeutic R&D
Mendus' lead product vididencel is an active immunotherapy for acute myeloid leukemia (AML) and other blood-borne tumors. In an international, multicenter Ph 2 trial, vididencel demonstrated durable clinical remissions in AML patients with measurable residual disease. Vididencel is currently studied in a Ph 2b combination trial with SoC and being prepared for a registration trial in AML. Mendus has earlier-stage pipeline programs addressing solid tumors and a technology platform for the expansion immune cells for therapeutic purposes, including tumor-infiltrating lymphocytes (TILs).
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}